Related Experiment Video

Updated: Jun 23, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

[Anemia in chronic kidney disease and its cardiovascular implications]

A Cases1, E Coll, S Collado

  • 1Servicio de Nefrología, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain. acases@clinic.ub.es

Medicina Clinica
|May 23, 2009
PubMed

Insights

Anemia in chronic kidney disease (CKD) increases cardiovascular risks. Erythropoiesis stimulating agents (ESA) help manage anemia, but recent guidelines suggest targeting moderate hemoglobin levels to avoid adverse outcomes.

Area of Science:

  • Nephrology
  • Cardiology
  • Hematology

Context:

  • Cardiovascular disease is the primary cause of mortality in chronic kidney disease (CKD) patients.
  • Anemia is a frequent complication of CKD, significantly contributing to left ventricular hypertrophy (LVH), heart failure, and increased cardiovascular morbidity and mortality.
  • Erythropoiesis stimulating agents (ESA) have revolutionized anemia management in CKD.

Purpose:

  • To review the role of ESA in managing anemia in CKD patients.
  • To evaluate the impact of anemia treatment on cardiovascular outcomes, including LVH and heart failure.
  • To provide evidence-based recommendations for target hemoglobin levels in CKD patients receiving ESA therapy.

Summary:

  • ESA therapy, by raising hemoglobin levels, has shown benefits in improving quality of life and reducing morbidity and mortality in CKD patients.
  • While early studies suggested benefits of full anemia correction, recent randomized controlled trials indicate no added advantage for LVH and potentially worse outcomes compared to partial correction.
  • Current guidelines recommend targeting hemoglobin levels between 11-12 g/dl for CKD patients undergoing ESA treatment.

Impact:

  • Optimizing anemia management in CKD patients can mitigate cardiovascular risks.
  • The findings support a more nuanced approach to anemia treatment, emphasizing partial correction to balance benefits and risks.
  • This evidence guides clinical practice and future research in managing cardiorenal anemia syndrome.

More Related Videos

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...